Regeneron’s Pasatru Approved for Adult FOP, Second Disease-Modifying Therapy

Company: Regeneron · Event Type: FDA Approval · Product: Pasatru (garetosmab-grts) · Mechanism: Activin A-Neutralizing Antibody · Indication: Fibrodysplasia Ossificans Progressiva · Announcement Date: August 19, 2026 Summary The FDA approved Regeneron’s Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults…